Loading...
Phase 1 Study of Belinostat (PXD-101) and Bortezomib (Velcade, PS-341) in Patients with Relapsed or Refractory Acute Leukemia and Myelodysplastic Syndrome
We report the results of a phase 1 dose-escalation study of belinostat and bortezomib in adult patients with acute leukemia or MDS or CML with blast crisis. Thirty-eight patients received IV belinostat days 1-5 and 8-12 with IV bortezomib days 1, 4, 8, and 11 every 21 days. QTc prolongation was the...
Na minha lista:
| Udgivet i: | Leuk Lymphoma |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8106643/ https://ncbi.nlm.nih.gov/pubmed/33356689 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428194.2020.1861270 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|